The estimated Net Worth of Halley E Gilbert is at least $1.12 Milione dollars as of 3 June 2024. Ms. Gilbert owns over 18,200 units of CytomX Therapeutics Inc stock worth over $31,211 and over the last 10 years she sold CTMX stock worth over $1,084,288. In addition, she makes $0 as Independent Director at CytomX Therapeutics Inc.
Halley has made over 16 trades of the CytomX Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently she exercised 18,200 units of CTMX stock worth $97,370 on 3 June 2024.
The largest trade she's ever made was exercising 60,000 units of CytomX Therapeutics Inc stock on 31 January 2020 worth over $601,200. On average, Halley trades about 6,963 units every 66 days since 2015. As of 3 June 2024 she still owns at least 23,825 units of CytomX Therapeutics Inc stock.
You can see the complete history of Ms. Gilbert stock trades at the bottom of the page.
Halley Gilbert serves as Independent Director of the Company. Currently, Ms. Gilbert serves as Senior Vice President, Corporate Development and Chief Administrative Officer at Ironwood Pharmaceuticals, Inc. having joined the company in 2008 as Vice President and General Counsel. At Ironwood, Ms. Gilbert oversees corporate and business development, legal, compliance and government affairs. Prior to this, Ms. Gilbert served in several roles at Cubist Pharmaceuticals, Inc. (acquired by Merck), including as Vice President, Deputy General Counsel, Assistant Secretary and Assistant General Counsel from 2002 to 2007. From 1999 to 2002, Ms. Gilbert held the position of Corporate Counsel at Genzyme Corporation. Ms. Gilbert began her career at the law firm of Skadden, Arps, Slate, Meagher & Flom LLP, where, serving as Corporate Associate from 1995 to 1998, she specialized in mergers and acquisitions and securities law. Ms. Gilbert currently serves on the board of Arcutis Biotherapeutics, a public biopharmaceutical company, and formerly served on the boards of Dermira, Inc. (acquired by Eli Lilly and Company) and Achaogen, Inc. Ms. Gilbert received a J.D. from Northwestern University School of Law and a B.A. from Tufts University.
Halley Gilbert is 50, she's been the Independent Director of CytomX Therapeutics Inc since 2020. There are 16 older and 1 younger executives at CytomX Therapeutics Inc. The oldest executive at CytomX Therapeutics Inc is Frederick W. Gluck, 86, who is the Co-Founder & Independent Director.
Halley's mailing address filed with the SEC is C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91361.
Over the last 10 years, insiders at CytomX Therapeutics Inc have traded over $57,157,858 worth of CytomX Therapeutics Inc stock and bought 662,000 units worth $7,876,720 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Harbor Master Investors (Ca... e James E Deerfield Mgmt L.P..... On average, CytomX Therapeutics Inc executives and independent directors trade stock every 20 days with the average trade being worth of $48,707. The most recent stock trade was executed by Jeffrey B Landau on 20 August 2024, trading 11,250 units of CTMX stock currently worth $14,738.
cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o
CytomX Therapeutics Inc executives and other stock owners filed with the SEC include: